We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+64.77%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$1.62B
AUM Growth
+$549M
Cap. Flow
+$182M
Cap. Flow %
11.25%
Top 10 Hldgs %
48.03%
Holding
65
New
8
Increased
19
Reduced
26
Closed
8

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$64.8M
2
RPTX
Repare Therapeutics
RPTX
+$62.4M
3
RCUS icon
Arcus Biosciences
RCUS
+$49.8M
4
XOMA
Xoma
XOMA
+$27.5M
5
MRUS
Merus
MRUS
+$22.4M

Top Sells

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$46.4M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$29M
3
RVMD icon
Revolution Medicines
RVMD
+$18.9M
4
SWTX
SpringWorks Therapeutics
SWTX
+$17.1M
5
CALA
Calithera Biosciences, Inc
CALA
+$14.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FWP
51
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$3.97M 0.24%
647,299
-278,425
-30% -$1.78M
BLRX
52
BioLineRX
BLRX
$12.1M
$2.88M 0.18%
42,159
-1,167
-3% -$79.7K
FSTX
53
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$1.38M 0.09%
235,293
-2,632
-1% -$15.2K
RGLS
54
DELISTED
Regulus Therapeutics
RGLS
$988K 0.06%
145,000
-14,292
-9% -$93.5K
ELDN icon
55
Eledon Pharmaceuticals
ELDN
$258M
$818K 0.05%
99,167
+61,122
+161% +$690K
VIRX
56
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$684K 0.04%
74,141
-102,857
-58% -$1.55M
EXEL icon
57
Exelixis
EXEL
$13.4B
$363K 0.02%
+15,300
New +$355K
AKRO
58
DELISTED
Akero Therapeutics
AKRO
– –
-282,862
Closed -$6M
CYTK icon
59
Cytokinetics
CYTK
$10.6B
– –
-3,938,280
Closed -$46.4M
LKFT
60
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.79B
– –
-7,674
Closed -$1.5M
KZR
61
DELISTED
Kezar Life Sciences
KZR
– –
-156,437
Closed -$6.82M
MRSN
62
DELISTED
Mersana Therapeutics
MRSN
– –
-94,896
Closed -$13.8M
ALPN
63
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-1,137,764
Closed -$3.28M
EIGR
64
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-2,268
Closed -$463K
PRVL
65
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
– –
-431,483
Closed -$5.26M
1 2
3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q2 2020 Portfolio in Review

As of Q2 2020, BVF Inc held 65 positions worth $1.62B, up 51% from $1.07B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

BVF Inc deployed $182M of net new capital in Q2 2020, opening 8 new positions and adding to 19 existing holdings. Its largest new stake was Repare Therapeutics: 1,944,546 shares worth $60.3M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier.

On the sell side, the largest reduction was Ionis Pharmaceuticals, an estimated $29M trimmed.

  • BVF Inc's largest Q2 2020 buy was Repare Therapeutics: 1,944,546 shares worth $60.3M.
  • BVF Inc added most to argenx in Q2 2020, an estimated $64.8M increase.
  • BVF Inc's biggest Q2 2020 reduction was Ionis Pharmaceuticals, cutting an estimated $29M.
  • BVF Inc fully exited Cytokinetics in Q2 2020, selling an estimated $46.4M.
  • BVF Inc's ten largest holdings make up 48% of its $1.62B portfolio in Q2 2020.
  • BVF Inc opened 8 new positions and closed 8 in Q2 2020.
  • BVF Inc's portfolio value rose 51% quarter-over-quarter to $1.62B.

Based on BVF Inc's 13F filing for Q2 2020, filed 14 Aug 2020.